NeuroSearch A/S' share capital and voting rights

Announcement                                                                    


NeuroSearch A/S' share capital and voting rights                      

On 9 September 2008, NeuroSearch increased its share capital with the issue of  
1,553 new shares of DKK 20 nominal value each at a price of DKK 248.39 per share
as a consequence of the exercise of warrants issued to employees and management 
in 2004.                                                                        

Pursuant to section 6 of Executive Order no. 1172 of 9 October 2007 on Issuers' 
Disclosure Obligations, it is hereby announced that at the end of September     
2008, the total nominal value of NeuroSearch A/S' share capital is DKK          
314,865,700, which is made up of 15,743,285 shares with a nominal value of DKK  
20 each, and corresponding to 314,865,700 votes.                                


Thomas Hofman-Bang                                                              
Chairman of the Board                                                           



Contact persons:                                                                
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate  
Communications, telephone: +45 4017 5103                                        




NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. The company's core business covers the          
development of novel drugs, based on a broad and well-established drug discovery
platform focusing on ion channels and CNS disorders. A substantial share of its 
activities is partner financed through a broad alliance with GlaxoSmithKline    
(GSK) and collaborations with, among others, Abbott and Astellas. NeuroSearch's 
drug pipeline comprises 14 clinical (Phase I-III) development programmes: ACR16 
for Huntington's disease (Phase III), tesofensine for obesity and in Type 2     
diabetes (Phase III in preparation), NS2359 for depression (Phase II) and ADHD  
(Phase II) in partnership with GSK, ABT-894 for ADHD (Phase II) and pain (Phase 
II) in partnership with Abbott, ACR16 for schizophrenia (Phase I) in partnership
with Astellas, ACR325 for Parkinson's disease (Phase II in preparation) and     
bipolar disorder (Phase II in preparation), ABT-107 and ABT-560 for the         
treatment of various CNS disorders - both (Phase I) in collaboration with       
Abbott, NSD-644 for pain (Phase I) in partnership with GSK, ACR343 for          
Parkinson's disease (Phase I) and NSD-788 for anxiety/depression (Phase I). In  
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and  
holds equity interests in several biotech companies.